Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 581,713 shares of the biopharmaceutical company’s stock after selling 67,510 shares during the period. Calamos Advisors LLC owned about 0.26% of Alexion Pharmaceuticals worth $56,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Alexion Pharmaceuticals by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after acquiring an additional 211,960 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock valued at $2,125,230,000 after acquiring an additional 199,298 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 57,650.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after acquiring an additional 3,630,846 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Alexion Pharmaceuticals by 0.5% in the 2nd quarter. Northern Trust Corp now owns 2,976,327 shares of the biopharmaceutical company’s stock valued at $389,840,000 after acquiring an additional 15,296 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock valued at $272,253,000 after acquiring an additional 13,426 shares during the last quarter. 93.26% of the stock is currently owned by institutional investors.

ALXN has been the topic of a number of recent analyst reports. Cowen reiterated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, October 16th. Stifel Nicolaus reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. Robert W. Baird set a $165.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on Alexion Pharmaceuticals in a report on Wednesday, July 31st. They issued an “overweight” rating and a $172.00 price objective on the stock. Finally, TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $159.76.

NASDAQ:ALXN traded up $2.63 during mid-day trading on Monday, reaching $101.04. 1,067,827 shares of the stock were exchanged, compared to its average volume of 1,741,548. The company has a 50 day simple moving average of $101.88 and a 200-day simple moving average of $118.85. The stock has a market capitalization of $22.42 billion, a P/E ratio of 14.25, a P/E/G ratio of 0.95 and a beta of 1.67. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.51. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The firm’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.07 EPS. As a group, research analysts predict that Alexion Pharmaceuticals, Inc. will post 9.06 EPS for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Limitations of analyzing profit margin

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.